PMID- 31040043 OWN - NLM STAT- MEDLINE DCOM- 20200110 LR - 20200110 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 215 IP - 6 DP - 2019 Jun TI - Prognostic role of Amphiregulin and the correlation with androgen receptor in invasive breast cancer. PG - 152414 LID - S0344-0338(19)30104-9 [pii] LID - 10.1016/j.prp.2019.04.006 [doi] AB - BACKGROUND: In androgen-sensitive prostate cancer, androgenic stimulation induces the synthesis of amphiregulin (AREG). Research is lacking on the role of AREG in invasive breast cancer and the co-expression with androgen receptor (AR) status. MATERIALS AND METHODS: The present study investigated the prognostic role of AREG in invasive breast cancer cases (N = 298) and the co-expression with the AR status as analysed by immunohistochemistry (IHC). RESULTS: The samples were divided into groups according to AREG expression levels: low/no expression (AREG(low/no)) and high expression (AREG(high)). As shown by cytoplasmic immunostaining, 46.0% (137/298) of invasive breast cancers were AREG(high), and 54.0% (161/298) of cases were AREG(low/no). Co-expression of the AR and AREG accounted for 62.4% (186/298) of cases. A Kaplan-Meier analysis revealed that AREG(high) and AR(+)/AREG(high) decreased patients' overall survival (OS) (P = 0.002 and P = 0.006, respectively) and disease-free survival (DFS) (P < 0.001 and P < 0.001, respectively). In Cox models, AR(+)/AREG(high) remained an independent prognostic indicator of OS and DFS in invasive breast cancer (hazard ratio [HR], 0.591, 95% confidence interval [CI], 0.407-0.859, P = 0.006; HR, 0.449, 95% CI, 0.236-0.853, P = 0.014, respectively). AREG(high) remained an independent prognostic indicator of OS and DFS in estrogen receptor (ER)-negative tumours (P < 0.05). CONCLUSIONS: This study suggested that AREG and the AR were co-expressed in invasive breast cancer. Thus, AREG and the AR may be valuable prognostic biomarkers in invasive breast cancer and promising therapeutic targets, especially in ER-negative breast cancer. CI - Copyright (c) 2019 Elsevier GmbH. All rights reserved. FAU - Xiang, Guomin AU - Xiang G AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. FAU - Liu, Fang AU - Liu F AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. FAU - Liu, Jing AU - Liu J AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. FAU - Meng, Qingxiang AU - Meng Q AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. FAU - Li, Nannan AU - Li N AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. FAU - Niu, Yun AU - Niu Y AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital. West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. Electronic address: yunniu0823@126.com. LA - eng PT - Journal Article DEP - 20190422 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (AR protein, human) RN - 0 (AREG protein, human) RN - 0 (Amphiregulin) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Androgen) SB - IM MH - Adult MH - Aged MH - Amphiregulin/*biosynthesis MH - Biomarkers, Tumor/analysis MH - Breast Neoplasms/metabolism/mortality/*pathology MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Middle Aged MH - Prognosis MH - Receptors, Androgen/*biosynthesis MH - Retrospective Studies OTO - NOTNLM OT - Amphiregulin OT - Androgen receptor OT - ER-negative breast cancer OT - Invasive breast cancer OT - Prognosis EDAT- 2019/05/02 06:00 MHDA- 2020/01/11 06:00 CRDT- 2019/05/02 06:00 PHST- 2019/01/16 00:00 [received] PHST- 2019/03/24 00:00 [revised] PHST- 2019/04/05 00:00 [accepted] PHST- 2019/05/02 06:00 [pubmed] PHST- 2020/01/11 06:00 [medline] PHST- 2019/05/02 06:00 [entrez] AID - S0344-0338(19)30104-9 [pii] AID - 10.1016/j.prp.2019.04.006 [doi] PST - ppublish SO - Pathol Res Pract. 2019 Jun;215(6):152414. doi: 10.1016/j.prp.2019.04.006. Epub 2019 Apr 22.